Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Double-blind Placebo-controlled Study of AMG 334 in Migraine Prevention
2014-004463-20Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing AMG 334 with Placebo (2 arms). Primary endpoint: Change from baseline in monthly migraine days at month 3. Started Jun 2015; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2014-004463-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004463-20.